Pharma companies delist patents from FDA's Orange Book following FTC challenges

Nicole DeFeudis

Editor

At least three pharma companies have requested to pull patents from an FDA database after the Federal Trade Commission challenged more than 100 patents it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pharma companies delist patents from FDA's Orange Book following FTC challenges

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

IGM Biosciences’ autoimmune pivot lasts three months after interim data disappoint

Versant unveils Light Horse with $62M and a partnership with Novartis

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Bayer says elinzanetant quelled hot flashes in women undergoing cancer treatment

Phar­ma com­pa­nies delist patents from FDA's Or­ange Book fol­low­ing FTC chal­lenges

Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Pharma companies delist patents from FDA's Orange Book following FTC challenges